Pan-Biome Pharmaceuticals is dedicated to advancing healthspan and longevity by developing innovative therapies aimed at delaying the onset of age-related diseases. The company focuses on the gut microbiome's role in health, particularly in relation to chronic conditions such as inflammatory bowel disease (IBD) and Alzheimer’s disease. By targeting the gut microbiome, Pan-Biome aims to create solutions that not only extend lifespan but also enhance the quality of life for individuals as they age.

The company’s research and development efforts are centered around a lead compound that leverages the therapeutic potential of the gut microbiome. This approach is grounded in the understanding that a balanced microbiome can significantly influence overall health and the progression of age-related diseases. Through its innovative pipeline, Pan-Biome seeks to address the challenges posed by chronic conditions, ultimately contributing to a healthier aging process for people worldwide.

Canada

Pan-Biome Pharmaceuticals, Inc, is a Vancouver-based preclinical biopharmaceutical company spun out two years ago with a focus on developing safe and highly effective drugs to promote healthy aging and healthspan. We recently developed a new generation of natural product-based small molecule compounds that exhibit a variety of beneficial biological activities with the potential to modulate important pathways that, when altered, can lead to the development of inflammatory, immune and degenerative diseases.

Pan-Biome

Company Details